Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-218.05M |
| Operating Margin | 0.00% |
| Return on Equity | -15.00% |
| Return on Assets | -11.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $21.41 |
| Price-to-Book | 1.93 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -13.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.08M |
| Float | $164.69M |
| % Insiders | 2.66% |
| % Institutions | 96.06% |
Volatility is currently expanding